Patents by Inventor Jeffrey M. Bergman

Jeffrey M. Bergman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7560546
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a sulfonyl indole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: July 14, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Christopher J. Dinsmore, Douglas C. Beshore, Jeffrey M. Bergman, Craig W. Lindsley
  • Publication number: 20090118200
    Abstract: The present invention is directed to proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: May 22, 2006
    Publication date: May 7, 2009
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Christopher D. Cox, George D. Hartman, Craig Lindsley, Swati Pal Mercer, Anthony J. Roecker, David B. Whitman
  • Publication number: 20090088452
    Abstract: The present invention is directed to substituted indole compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: November 17, 2006
    Publication date: April 2, 2009
    Inventors: Paul J. Coleman, Anthony J. Roecker, Jeffrey M. Bergman
  • Publication number: 20080287414
    Abstract: The present invention relates to tricyclic pyrazoles according to Formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: June 27, 2005
    Publication date: November 20, 2008
    Applicant: MERCK & CO., INC.
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Mark E. Fraley, Robert M. Garbaccio, George D. Hartman, Chunze Li, Lou Anne Neilson, Christy M. Olson, Edward S. Tasber
  • Publication number: 20080227778
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 17, 2004
    Publication date: September 18, 2008
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman, Charles J. McIntyre, David A. Claremon
  • Publication number: 20080132490
    Abstract: The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: November 30, 2007
    Publication date: June 5, 2008
    Inventors: Jeffrey M. Bergman, Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, Swati P. Mercer, Anthony J. Roecker
  • Patent number: 6562823
    Abstract: The present invention is directed to peptidomimetic piperazine-containing macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: May 13, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman, Samuel L. Graham, Diem N. Nguyen, Gerald E. Stokker, Theresa M. Williams, C. Blair Zartman
  • Publication number: 20020193283
    Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Application
    Filed: February 16, 2001
    Publication date: December 19, 2002
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman
  • Publication number: 20020052363
    Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Application
    Filed: February 16, 2001
    Publication date: May 2, 2002
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman
  • Publication number: 20020052380
    Abstract: The present invention comprises piperazinone-containing compounds, which may be useful as inhibitors of prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Application
    Filed: January 26, 2001
    Publication date: May 2, 2002
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman
  • Patent number: 6376496
    Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: April 23, 2002
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, William C. Lumma, Jr., John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Jeffrey M. Bergman
  • Patent number: 6355643
    Abstract: The present invention comprises unsubstituted and substituted piperazine-containing compounds having alkanoyl, alkylsulfonyl, alkylamido or alkoxycarbonyl substituents, and having the formula A, which inhibit prenyl-protein transferases. In particular, the invention relates to prenyl-protein transferase inhibitors which are efficacious in vivo as inhibitors of geranylgeranyl-protein transferase type I (GGTase-I) and that inhibit the cellular processing of both the H-Ras protein and the K4B-Ras protein. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: March 12, 2002
    Assignee: Merck & Co., Inc.
    Inventors: William C. Lumma, John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Christopher J. Dinsmore, Jeffrey M. Bergman
  • Publication number: 20020010184
    Abstract: The present invention comprises piperazinone-containing compounds which inhibit prenyl-protein transferases, including famesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Application
    Filed: January 26, 2001
    Publication date: January 24, 2002
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman
  • Patent number: 6329376
    Abstract: The present invention is directed to peptidomimetic piperazine-containing macrocyclic compounds which inhibit a prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: December 11, 2001
    Assignee: Merck & Co., Inc.
    Inventor: Jeffrey M. Bergman
  • Patent number: 6103723
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: October 13, 1998
    Date of Patent: August 15, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Jeffrey M. Bergman, Christopher J. Dinsmore, Samuel L. Graham
  • Patent number: 5972984
    Abstract: The present invention comprises low molecular weight peptidyl compounds that inhibit the farnesyl-protein transferase. Furthermore, these compounds differ from the mono- or dipeptidyl analogs previously described as inhibitors of farnesyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.
    Type: Grant
    Filed: October 29, 1997
    Date of Patent: October 26, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Jeffrey M. Bergman, S. Jane deSolms, Chrisopher J. Dinsmore, Robert P. Gomez, Suzanne C. MacTough, Kelly M. Solinsky, Theresa M. Williams
  • Patent number: 5756528
    Abstract: The present invention comprises low molecular weight peptidyl compounds that inhibit the farnesyl-protein transferase. Furthermore, these compounds differ from the mono- or dipeptidyl analogs previously described as inhibitors of farnesyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: May 26, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Jeffrey M. Bergman, Chrisopher J. Dinsmore, Robert P. Gomez, Suzanne C. MacTough, Kelly M. Solinsky, Theresa M. Williams
  • Patent number: 5378838
    Abstract: Benzodiazepine analogs of the formula: ##STR1## are disclosed which are antagonists of gastrin and cholecystokinin (CCK).
    Type: Grant
    Filed: January 13, 1993
    Date of Patent: January 3, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Jeffrey M. Bergman, Roger M. Freidinger, Mark G. Bock